open access

Vol 76, No 7 (2018)
Original articles
Published online: 2018-02-23
Submitted: 2017-10-02
Accepted: 2018-02-19
Get Citation

Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry

Jacek Migaj, Marta Kałużna-Oleksy, Jadwiga Nessler, Grzegorz Opolski, Marisa G. Crespo-Leiro, Aldo P. Maggioni, Stefan Grajek, Piotr Ponikowski, Jarosław Drożdż, Ewa Straburzyńska-Migaj
DOI: 10.5603/KP.a2018.0059
·
Pubmed: 29476617
·
Kardiol Pol 2018;76(7):1064-1072.

open access

Vol 76, No 7 (2018)
Original articles
Published online: 2018-02-23
Submitted: 2017-10-02
Accepted: 2018-02-19

Abstract

Background: Digoxin is used in the treatment of atrial fibrillation (AF) and heart failure (HF). It was reported to increase the risk of death in HF. Studies on digoxin are based mainly on patients treated some years ago, before the era of common b-blocker use.

Aim: This study aims to show the influence of digoxin in a modern cohort of HF patients on top of the contemporary guideline-directed treatment.

Methods: This study retrospectively analyses the Polish part of the European Society of Cardiology Heart Failure Long-Term Registry. It includes 912 patients treated for HF between February 2012 and January 2013, and followed until May 2014. At baseline, 19.1% took digoxin, 89.6% angiotensin convertase enzyme inhibitors or angiotensin receptor blockers, 91.9% b-blockers, and 69.4% mineralocorticoid receptor antagonists.

Results: Digoxin is associated with increased risk of death after adjustment for significant covariates in patients who have HF with reduced ejection fraction (HFrEF) but no AF history (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.23–5.19; p = 0.011), and it does not influence significantly the risk of hospitalisation (adjusted HR 1.46, 95% CI 1.05–1.72; p = 0.11). Digoxin use shows no significant association with the risk of death or hospitalisation in patients with AF and HFrEF or HF with preserved ejection fraction (HFpEF). Patients on digoxin present a significantly worse clinical status with lower left ventricular ejection fraction and higher New York Heart Association class, and fewer of them received the guideline-directed treatment.

Conclusions: Digoxin is associated with increased risk of death in HFrEF patients without AF history receiving the guideline- -directed treatment. Digoxin seems to be employed in patients with worse clinical status, which may at least partially explain its association with increased risk of death.

Abstract

Background: Digoxin is used in the treatment of atrial fibrillation (AF) and heart failure (HF). It was reported to increase the risk of death in HF. Studies on digoxin are based mainly on patients treated some years ago, before the era of common b-blocker use.

Aim: This study aims to show the influence of digoxin in a modern cohort of HF patients on top of the contemporary guideline-directed treatment.

Methods: This study retrospectively analyses the Polish part of the European Society of Cardiology Heart Failure Long-Term Registry. It includes 912 patients treated for HF between February 2012 and January 2013, and followed until May 2014. At baseline, 19.1% took digoxin, 89.6% angiotensin convertase enzyme inhibitors or angiotensin receptor blockers, 91.9% b-blockers, and 69.4% mineralocorticoid receptor antagonists.

Results: Digoxin is associated with increased risk of death after adjustment for significant covariates in patients who have HF with reduced ejection fraction (HFrEF) but no AF history (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.23–5.19; p = 0.011), and it does not influence significantly the risk of hospitalisation (adjusted HR 1.46, 95% CI 1.05–1.72; p = 0.11). Digoxin use shows no significant association with the risk of death or hospitalisation in patients with AF and HFrEF or HF with preserved ejection fraction (HFpEF). Patients on digoxin present a significantly worse clinical status with lower left ventricular ejection fraction and higher New York Heart Association class, and fewer of them received the guideline-directed treatment.

Conclusions: Digoxin is associated with increased risk of death in HFrEF patients without AF history receiving the guideline- -directed treatment. Digoxin seems to be employed in patients with worse clinical status, which may at least partially explain its association with increased risk of death.

Get Citation

Keywords

b-blockers, digoxin, heart failure, hospitalisations, mortality

About this article
Title

Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 7 (2018)

Pages

1064-1072

Published online

2018-02-23

DOI

10.5603/KP.a2018.0059

Pubmed

29476617

Bibliographic record

Kardiol Pol 2018;76(7):1064-1072.

Keywords

b-blockers
digoxin
heart failure
hospitalisations
mortality

Authors

Jacek Migaj
Marta Kałużna-Oleksy
Jadwiga Nessler
Grzegorz Opolski
Marisa G. Crespo-Leiro
Aldo P. Maggioni
Stefan Grajek
Piotr Ponikowski
Jarosław Drożdż
Ewa Straburzyńska-Migaj

References (34)
  1. Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.]. Kardiol Pol. 2016; 74(10): 1037–1147.
  2. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336(8): 525–533.
  3. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015; 36(28): 1831–1838.
  4. Madelaire C, Schou M, Nelveg-Kristensen KE, et al. Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. Int J Cardiol. 2016; 221: 944–950.
  5. Qureshi W, O'Neal WT, Soliman EZ, et al. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol J. 2016; 23(3): 333–343.
  6. Al-Khateeb M, Qureshi WT, Odeh R, et al. The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. Int J Cardiol. 2017; 228: 214–218.
  7. Katz A, Maor E, Leor J, et al. Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. Int J Cardiol. 2016; 221: 198–204.
  8. Chamaria S, Desai AM, Reddy PC, et al. Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. Cardiol Res Pract. 2015; 2015: 314041.
  9. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015; 351: h4451.
  10. Andrey JL, Romero S, García-Egido A, et al. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. Int J Clin Pract. 2011; 65(12): 1250–1258.
  11. Ahmed A, Waagstein F, Pitt B, et al. Digitalis Investigation Group. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol. 2009; 103(1): 82–87.
  12. Erath JW, Vamos M, Hohnloser SH. Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients. Eur Heart J Cardiovasc Pharmacother. 2016; 2(3): 168–174.
  13. Butler J, Anand IS, Kuskowski MA, et al. Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010; 16(5): 191–195.
  14. Freeman JV, Yang J, Sung SH, et al. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013; 6(5): 525–533.
  15. Dhaliwal AS, Bredikis A, Habib G, et al. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol. 2008; 102(10): 1356–1360.
  16. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006; 27(2): 178–186.
  17. Testani JM, Brisco MA, Tang WH, et al. Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail. 2013; 19(5): 295–302.
  18. Bourge RC, Fleg JL, Fonarow GC, et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med. 2013; 126(8): 701–708.
  19. Hashim T, Elbaz S, Patel K, et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014; 127(2): 132–139.
  20. Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015; 385(9985): 2363–2370.
  21. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol. 2009; 103(2): 248–254.
  22. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013; 34(20): 1481–1488.
  23. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol. 2014; 114(3): 401–406.
  24. Allen LA, Fonarow GC, Simon DN, et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015; 65(25): 2691–2698.
  25. Konstantinou DM, Karvounis H, Giannakoulas G. Digoxin in heart failure with a reduced ejection fraction: a risk factor or a risk marker. Cardiology. 2016; 134(3): 311–319.
  26. Adams KF, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail. 2016; 18(8): 1072–1081.
  27. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013; 15(5): 551–559.
  28. Ather S, Peterson LE, Divakaran VG, et al. Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011; 150(3): 264–269.
  29. Ahmed A, Bourge R, Fonarow G, et al. Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure. Am J Med. 2014; 127(1): 61–70.
  30. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006; 114(5): 397–403.
  31. Powell BD, Saxon LA, Boehmer JP, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013; 62(18): 1674–1679.
  32. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008; 359(10): 1009–1017.
  33. Bavendiek U, Aguirre Davila L, Koch A, et al. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017; 38(27): 2095–2099.
  34. Fedyk-Łukasik M, Wizner B, Opolski G, et al. Quality of care of hospitalised patients with heart failure in Poland in 2013: results of the second nationwide survey. Kardiol Pol. 2017; 75(6): 527–534.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl